Quick Answer
Nuo Therapeutics, Inc. reported Diluted EPS of $0.03 per share (loss) for fiscal year 2021.
Nuo Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2021 | -$0.03 | -111.1% |
| 2020 | $0.27 | +640.0% |
| 2019 | -$0.05 | +28.6% |
| 2018 | -$0.07 | +93.1% |
| 2017 | -$1.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $0.00 | +100.0% | +100.0% |
| June 30, 2019 | -$0.02 | +33.3% | +33.3% |
| March 31, 2019 | -$0.03 | +0.0% | +0.0% |
| September 30, 2018 | -$0.03 | +66.7% | +0.0% |
| June 30, 2018 | -$0.03 | +92.3% | +0.0% |
| March 31, 2018 | -$0.03 | +82.4% | +66.7% |
| September 30, 2017 | -$0.09 | +52.6% | +76.9% |
| June 30, 2017 | -$0.39 | -200.0% | -129.4% |
- Nuo Therapeutics, Inc. showed a decrease of -111.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2021 period, Nuo Therapeutics, Inc.’s diluted eps has grown by 97.1% (from $1.02 per share (loss) to $0.03 per share (loss)).
- The most recent figure is from Nuo Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on April 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: